文献速递抗菌药物管理药物相互作用

多重耐药革兰阴性菌新药:管理时机已到

New Drugs for Multidrug-Resistant Gram-Negative Organisms: Time for Stewardship.
PubMed 文献 · Drugs · 2019-01-01

综述指出碳青霉烯耐药肠杆菌目、铜绿假单胞菌及广泛耐药鲍曼不动杆菌耐药率上升,近十年多个新抗生素针对此类病原体研发。部分β-内酰胺/β-内酰胺酶抑制剂复方及非β-内酰胺类药物对A、C、D类β-内酰胺酶产菌有体外活性,但阿维巴坦和伐博巴坦对金属β-内酰胺酶无体外活性。截至2019年2月,FDA批准头孢他啶-阿维巴坦、美罗培南-伐博巴坦、普拉佐米星和依拉环素治疗部分CRE相关感染;严格抗菌药物管理政策结合表型试验及多重PCR检测对有效处方和降低耐药负担重要。

要点

  • 头孢他啶-阿维巴坦、美罗培南-伐博巴坦对金属β-内酰胺酶产菌无体外活性。
  • 头孢吡肟-齐德巴坦、氨曲南-阿维巴坦、头孢地尔等对部分B类酶产菌有体外活性。
  • 严格抗菌药物管理政策结合表型试验和多重PCR检测对CRE感染处方重要。

核心结论

  • 新型抗生素研发成功,但需严格实施抗菌药物管理政策并结合表型试验和多重PCR检测以有效处方和降低CRE耐药负担。

研究设计与样本

  • 综述,未报告系统检索范围。

主要发现

  • 碳青霉烯耐药肠杆菌目、铜绿假单胞菌和广泛耐药鲍曼不动杆菌耐药率逐渐上升,威胁全球医疗系统。
  • 多数新抗生素对Ambler A、C、D类β-内酰胺酶产菌有良好体外活性,但阿维巴坦和伐博巴坦对金属β-内酰胺酶无体外活性。
  • 头孢吡肟-齐德巴坦、氨曲南-阿维巴坦、VNRX-5133、头孢地尔、普拉佐米星和依拉环素对部分或全部B类酶产菌有体外活性。
  • 德拉沙星对超广谱和AmpC β-内酰胺酶产肠杆菌目有活性,但对CRE无体外活性。
  • Murepavadin对碳青霉烯耐药和黏菌素耐药铜绿假单胞菌有特异性活性。

关键数值与推荐

  • 截至2019年2月,FDA批准头孢他啶-阿维巴坦、美罗培南-伐博巴坦、普拉佐米星和依拉环素治疗部分CRE相关感染。

临床怎么用

  • 医院应严格实施抗菌药物管理政策,结合表型试验和多重PCR检测常见β-内酰胺酶/碳青霉烯酶,以指导有效处方并降低CRE耐药负担。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A gradual rise in drug-resistant trends among Gram-negative organisms, especially carbapenem-resistant (CR) Enterobacteriaceae (CRE), CR-Pseudomonas aeruginosa, and extensively-drug-resistant (XDR) Acinetobacter baumannii, poses an enormous threat to healthcare systems worldwide. In the last decade, many pharmaceutical companies have devoted enormous resources to the development of new potent antibiotics against XDR Gram-negative pathogens, particularly CRE. Some of these novel antibiotics against CRE strains are β-lactam/β-lactamase-inhibitor combination agents, while others belong to the non-β-lactam class. Most of these antibiotics display good in vitro activity against the producers of Ambler class A, C, and D β-lactamase, although avibactam and vaborbactam are not active in vitro against metallo-β-lactamase (MβL) enzymes. Nevertheless, in vitro efficacy against the producers of some or all class B enzymes (New Delhi MβL, Verona integron-encoded MβL, etc) has been shown with cefepime-zidebactam, aztreonam-avibactam, VNRX-5133, cefiderocol, plazomicin, and eravacycline. As of Feburary 2019, drugs approved for treatment of some CRE-related infections by the US Food and Drug Administration included ceftazidime-avibactam, meropenem-vaborbactam, plazomicin, and eravacycline. Although active against extended-spectrum and AmpC β-lactamase-producing Enterobacteriaceae, delafloxacin does not show in vitro activity against CRE. Murepavadin is shown to be specifically active against CR- and colistin-resistant P. aeruginosa strains. Despite successful development of novel antibiotics, strict implementation of an antibiotic stewardship policy in combination with the use of well-established phenotypic tests and novel multiplex PCR methods for detection of the most commonly encountered β-lactamases/carbapenemases in hospitals is important for prescribing effective antibiotics against CRE and decreasing the resistance burden due to CRE.

来源:Drugs,查看原文。版权归原作者所有。

引用

  1. Jean SS, Gould IM, Lee WS, et al. New Drugs for Multidrug-Resistant Gram-Negative Organisms: Time for Stewardship. Drugs. 2019. PMID: 30972660. doi:10.1007/s40265-019-01112-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。